We are not finalizing our proposal to revise references to 425.512(b)(4) and (b)(5) (which we proposed to redesignate as paragraphs (b)(3) and (b)(4))
Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH
If you have a normal BMI but show signs of insulin resistance, borderline elevated blood sugar, or a strong family history of diabetes, you may qualify for personalized GLP-1 therapy
[1] It is important to note that the FDA has not yet approved GLP-1 agonists for treating type 1 diabetes, but some healthcare providers may prescribe them off-label
The 2019 Global Consensus Position Statement on testosterone use in women established that testosterone therapy is associated with improvements in lean mass, bone density, and sexual function in postmenopausal women [24]
ACS Nano, 2023, 17: 69126921 Gao X, Pan K, Zhao B, et al